Akathisia Management: 2026 PMHNP Decision Tree

A patient on risperidone keeps saying they cannot sit still and feel anxious all the time. The new PMHNP doubles the antipsychotic. Two weeks later the patient is in the emergency department.

That misread costs careers and lives. Akathisia is mistaken for anxiety, agitation, or worsening psychosis in roughly half of new patients on dopamine blockers, and the standard reflex of pushing the dose makes the underlying problem worse. Treatment-emergent akathisia is independently linked to suicidality, treatment dropout, and violence toward self and others — yet it is one of the most fixable side effects in clinical psychiatry when the diagnosis is made on the first visit.

This is the 2026 PMHNP decision tree for spotting akathisia early, scoring it with the right tool, choosing between mirtazapine and propranolol as first-line adjuncts, and avoiding the documented mistakes that turn a manageable side effect into a treatment-ending event.

Why akathisia gets missed — the anxiety mimic problem

Akathisia produces a subjective sense of inner restlessness and an objective inability to stay still. Patients tap, pace, rock, and shift their weight. They describe the experience as crawling out of their skin or needing to move — language a new PMHNP hears as anxiety, especially in patients with comorbid anxiety disorders or trauma histories.

The mistake is structural. Antipsychotics are prescribed for conditions that include agitation as a core symptom. When a patient on a new dopamine blocker reports more restlessness, the clinical reflex points back at the underlying illness, and the drug rarely gets blamed at the first visit.

Onset matters. Acute akathisia appears within hours to weeks of starting or increasing a dopamine blocker. Tardive akathisia emerges after months on therapy and behaves differently — it persists after the drug is withdrawn and responds less reliably to the first-line agents. Roughly 20 to 30 percent of patients on first-generation antipsychotics and 10 to 20 percent on second-generation antipsychotics develop acute akathisia, with the highest rates on aripiprazole, lurasidone, and haloperidol.

“Akathisia is the side effect that ruins more antipsychotic trials than weight gain, but new PMHNPs almost never name it on the first visit,” says Lindsay Hill, DNP, PMHNP-BC, founder of the Psych NP Fellowship. “We train fellows to ask ‘are you moving more than you want to?’ rather than ‘are you anxious?’ — the language flips the differential.”

How to score it correctly — the BARS in two minutes

The Barnes Akathisia Rating Scale (BARS) is the standard. It has four items: objective movement on observation, subjective awareness of restlessness, subjective distress about the restlessness, and a global clinical rating from 0 to 5. The first three items are scored 0 to 3. The total subjective-plus-objective score ranges 0 to 9.

The protocol matters more than the score. The clinician observes the patient seated for two minutes, then standing for two minutes, before scoring. Patients minimize the movement when they know they are being watched, so a one-minute glance at the start of the visit misses mild and moderate cases. A global score of 2 or higher warrants treatment. A score of 3 or higher is moderate to severe and warrants same-week intervention, not a six-week follow-up.

PMHNPs should document a BARS at antipsychotic initiation, at every dose change, and at every follow-up for the first three months. After that, every six months is reasonable for stable patients. The score belongs in the note alongside the AIMS — they are different scales for different problems and they do not substitute for each other.

The 2026 first-line algorithm — mirtazapine, propranolol, B6, benztropine

Step 1 is always the same: can the offending antipsychotic be reduced or switched? If the patient is on aripiprazole 30 mg for unipolar depression augmentation, dropping to 5 mg may resolve the akathisia entirely. If switching is clinically safe, moving from aripiprazole or haloperidol to quetiapine, olanzapine, or iloperidone lowers D2 occupancy and akathisia risk in one step.

When dose reduction and switch are not viable, add an anti-akathisia agent.

Mirtazapine 15 mg at bedtime. A 2023 network meta-analysis of 15 randomized trials ranked mirtazapine first for effect size, ahead of propranolol, vitamin B6, trazodone, and biperiden. It works through 5-HT2A antagonism, takes 3 to 7 days to show effect, and adds a sleep and appetite benefit in patients who need them. Doses above 30 mg can paradoxically worsen akathisia — stay at 15 mg.

Propranolol 10–30 mg three times daily. Still a strong first choice in patients without asthma, bradycardia, or hypotension. Start 10 mg three times daily, titrate to 20 mg three times daily over a week. Effect onset is faster than mirtazapine, sometimes within 24 to 48 hours. Check resting heart rate and blood pressure before each increase, and hold or reduce if the heart rate drops below 55 or systolic blood pressure below 100.

Vitamin B6 (pyridoxine) 600–1200 mg per day. Two randomized trials show benefit at 1200 mg per day. Slower onset than propranolol, fewer drug interactions, and almost zero contraindications. A reasonable option when beta-blockade is contraindicated and mirtazapine is unavailable or refused.

Benztropine 1–2 mg twice daily. Strong tradition, weak evidence for pure akathisia. Benztropine works better for parkinsonism than for akathisia and adds anticholinergic load — constipation, urinary retention, cognitive blunting, and an increased risk of tardive dyskinesia over the long term. Reserve for cases with mixed parkinsonism plus akathisia.

Clonazepam 0.5–1 mg at bedtime, short-term only. Effective acutely, but the risk of dependence, falls in elderly patients, and rebound on discontinuation makes it a bridge to another agent — not a destination.

What most new PMHNPs get wrong about akathisia

The single most common mistake is treating akathisia as if it were anxiety, then doubling the antipsychotic. Roughly half of misdiagnosed patients receive a dose increase before the correct diagnosis is made, which adds 4 to 8 weeks of suffering and roughly triples the risk of nonadherence to the antipsychotic class for the rest of the patient’s life. Patients remember the experience. They tell the next prescriber that the medication made them feel like jumping out of their skin, and a second-line trial of any antipsychotic gets refused.

The second mistake is reaching for benztropine reflexively. Decades of clinical habit point clinicians toward anticholinergics, but the controlled data favor mirtazapine, propranolol, and B6. Benztropine layered on top of an antipsychotic also raises the risk of constipation, urinary retention, cognitive blunting, and tardive dyskinesia. The drug treats parkinsonism well — it does not treat akathisia well.

The third mistake is stopping treatment too soon. Acute akathisia can persist for weeks after the offending drug is dose-reduced. Patients who experience early relief from propranolol or mirtazapine and stop within 7 days frequently relapse, and the second course is harder to sell. Plan a minimum four-week course of any anti-akathisia agent at therapeutic dose, then taper over 1 to 2 weeks while monitoring BARS at each visit.

The fourth mistake is missing the SSRI angle. SSRI-induced akathisia is well-documented, especially in the first two weeks of a new SSRI or after a dose increase. A patient who reports new restlessness 10 days into sertraline is not having a panic disorder relapse — they are signaling that the SSRI dose climbed too fast.

Monitoring after you start treatment

Document a BARS at every visit while the patient is on adjunct therapy. The treatment goal is a total subjective-plus-objective score under 2 and a global clinical rating of 0 or 1. A persistent BARS of 2 or higher after two weeks at the target dose of mirtazapine or propranolol is the signal to escalate — combine with the second agent, return to step 1 (dose reduction or antipsychotic switch), or both.

If the patient is on propranolol, recheck resting heart rate and blood pressure at each visit. Hold or reduce if the heart rate drops below 55 or the systolic blood pressure below 100. Caution with patients on insulin — beta-blockade masks the adrenergic warning signs of hypoglycemia. If the patient is on mirtazapine, monitor weight at month one and month three. A 5-pound gain in the first month is the early signal; document and discuss before the patient stops the agent on their own.

Reassess the underlying psychiatric indication every 4 to 6 weeks. Akathisia that resolves quickly with an adjunct may signal the antipsychotic dose can come down without losing therapeutic effect. Persistent akathisia despite optimized adjunct therapy is grounds to switch to a lower-affinity agent — even if the index symptoms are well controlled — because the long-term adherence cost of unmanaged akathisia is higher than the short-term cost of a second medication change.

The bottom line. Akathisia is the side effect that ends more antipsychotic trials than weight gain, and it is the easiest one to fix when caught on the first visit. Score every antipsychotic patient with BARS. Reduce or switch when possible. Reach for mirtazapine 15 mg at bedtime or propranolol 10–30 mg three times daily as first-line adjuncts. Reserve benztropine for parkinsonism and benzodiazepines for short bridges.

The single move that prevents the most damage this week is replacing “are you anxious?” with “are you moving more than you want to?” — that one question pulls a third of missed akathisia cases out of the noise before the antipsychotic gets escalated.

This content is for educational purposes and does not replace individualized clinical judgment or supervision. Dosing examples, monitoring schedules, and treatment thresholds summarized here are general and may not apply to a specific patient — verify against current FDA labeling, drug-specific prescribing information, and supervisory consultation before making clinical decisions.